Home›Rosuvastatin

Rosuvastatin

HMG-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitors

Route: Oral

89 interactions on record

Rosuvastatin has 89 known drug interactions based on U.S. FDA drug labeling data. Of these, 11 are contraindicated combinations that should be avoided entirely. 34 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Asciminib, Cobicistat, Darunavir. Patients taking Rosuvastatin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 89
Contraindicated: 11
Major: 34
Moderate: 30

Contraindicated (11)

Rosuvastatin + Asciminib— Avoid concomitant use of SCEMBLIX at all recommended doses due to increased risk of rosuvastatin adverse reactions.
Rosuvastatin + Cobicistat— Other HMG-CoA reductase inhibitors: e.g., atorvastatin rosuvastatin ↑ HMG-CoA reductase inhibitors Coadministration of a…
Rosuvastatin + Darunavir— Lipid Modifying Agents: HMG-CoA reductase inhibitors: lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin Ot…
Rosuvastatin + Darunavir 600 Mg— Lipid Modifying Agents: HMG-CoA reductase inhibitors : lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin O…
Rosuvastatin + Darunavir Ethanolate And Cobicistat— atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvast…
Rosuvastatin + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ ro…
Rosuvastatin + Ledipasvir And Sofosbuvir— Combination may significantly increase rosuvastatin exposure. Concomitant use with rosuvastatin is not recommended.
Rosuvastatin + Lopinavir And Ritonavir— Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyc…
Rosuvastatin + Ritonavir— Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyce…
Rosuvastatin + Ritonavir 100 Mg— Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyce…
Rosuvastatin + Sofosbuvir, Velpatasvir, And Voxilaprevir— Combination increases rosuvastatin exposure. Use with rosuvastatin tablets is not recommended.

Major (34)

Rosuvastatin + Atazanavir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Capmatinib— Capmatinib increased rosuvastatin exposure more than 2.1-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
Rosuvastatin + Colchicine— Cases of myopathy, including rhabdomyolysis, have been reported with rosuvastatin coadministered with colchicine. Cautio…
Rosuvastatin + Cyclosporine— Cyclosporine increased rosuvastatin exposure 7-fold, significantly increasing the risk of myopathy and rhabdomyolysis. D…
Rosuvastatin + Danicopan— Danicopan significantly increased rosuvastatin exposure. Dose should not exceed 10 mg once daily when used concomitantly…
Rosuvastatin + Darolutamide— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily.
Rosuvastatin + Dasabuvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Rosuvastatin + Elbasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Elbasvir And Grazoprevir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Rosuvastatin + Eltrombopag— OATP1B1 and BCRP substrate; eltrombopag increases exposure. 50% dose reduction was recommended in clinical trials.
Rosuvastatin + Enasidenib— Enasidenib increased rosuvastatin exposure more than 2.4-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
Rosuvastatin + Febuxostat— Febuxostat increased rosuvastatin exposure more than 1.9-fold, increasing the risk of myopathy and rhabdomyolysis. Do no…
Rosuvastatin + Fostamatinib— Fostamatinib increased rosuvastatin exposure more than 2.0-fold, increasing the risk of myopathy and rhabdomyolysis. Do …
Rosuvastatin + Gemfibrozil— Avoid concomitant use of gemfibrozil with rosuvastatin. If concomitant use cannot be avoided, initiate rosuvastatin at 5…
Rosuvastatin + Glecaprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Glecaprevir And Pibrentasvir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Rosuvastatin + Grazoprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Ledipasvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.
Rosuvastatin + Lopinavir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Ombitasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Oral Anticoagulants— Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin and monitor frequently upon initiation or al…
Rosuvastatin + Paritaprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Pibrentasvir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Regorafenib— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Rosuvastatin + Resmetirom— REZDIFFRA increases plasma concentrations of rosuvastatin; limit daily dosage to 20 mg to reduce risk of statin-related …
Rosuvastatin + Simeprevir— Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Si…
Rosuvastatin + Sofosbuvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simepre…
Rosuvastatin + Teriflunomide— Teriflunomide increased rosuvastatin exposure more than 2.5-fold, increasing the risk of myopathy and rhabdomyolysis. Do…
Rosuvastatin + Tipranavir— HMG-CoA Reductase Inhibitors: Atorvastatin Rosuvastatin ↑ Atorvastatin ↓ Hydroxy-atorvastatin metabolites ↑ Rosuvastatin…
Rosuvastatin + Velpatasvir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simepre…
Rosuvastatin + Velpatasvir And Sofosbuvir— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Rosuvastatin + Voclosporin— OATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec…
Rosuvastatin + Voxilaprevir— Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.

Moderate (30)

Rosuvastatin + Aluminum & Magnesium Hydroxides— Antacids may reduce rosuvastatin absorption. Administer rosuvastatin at least 2 hours before the antacid.
Rosuvastatin + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol— Co-administration increases AUC of ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Elagolix— Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.
Rosuvastatin + Elagolix And Estradiol And Norethisterone— Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.
Rosuvastatin + Eltrombopag Olamine— 7.2 Transporters Use caution when concomitantly administering PROMACTA and drugs that are substrates of OATP1B1 (e.g., a…
Rosuvastatin + Eluxadoline— Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rha…
Rosuvastatin + Fenofibrate— No clinically significant increase in AUC observed, but risk of myopathy is increased with concomitant use of fenofibrat…
Rosuvastatin + Fibrates— Use with fibrates increases risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuva…
Rosuvastatin + Fosamprenavir— Fosamprenavir/ritonavir produces little or no change in rosuvastatin exposure. Caution should be exercised when coadmini…
Rosuvastatin + Fostemsavir Tromethamine— Statins: Rosuvastatin b Atorvastatin Fluvastatin Pitavastatin Simvastatin ↑Rosuvastatin ↑Atorvastatin ↑Fluvastatin ↑Pita…
Rosuvastatin + Leflunomide— Teriflunomide may increase exposure of rosuvastatin. Dose should not exceed 10 mg once daily.
Rosuvastatin + Lenacapavir Sodium— Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazo…
Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol Tablets— Rosuvastatin increases AUC of ethinyl estradiol by approximately 20 to 25% when co-administered with certain COCs.
Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate— Increases AUC values for ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Levonorgestrel/Ethinyl Estradiol And Ethinyl Estradiol— Increases systemic exposure of ethinyl estradiol by approximately 20-25 percent.
Rosuvastatin + Momelotinib— Momelotinib is a BCRP inhibitor that may increase rosuvastatin exposure. Initiate rosuvastatin at 5 mg and do not increa…
Rosuvastatin + Niacin— Lipid-modifying doses (≥1 g/day) of niacin increase risk of adverse skeletal muscle effects with rosuvastatin. Caution s…
Rosuvastatin + Norelgestromin And Ethinyl Estradiol— Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate— Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Norethindrone Acetate/Ethinyl Estradiol— Increases AUC values for ethinyl estradiol by approximately 20 to 25%.
Rosuvastatin + Norethindrone And Ethinyl Estradiol— May increase ethinyl estradiol AUC by approximately 20-25% when co-administered.
Rosuvastatin + Norgestimate And Ethinyl Estradiol— Co-administration increases AUC of ethinyl estradiol by approximately 20-25%, potentially increasing hormone exposure.
Rosuvastatin + Norgestrel And Ethinyl Estradiol— Increases AUC of ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Oteseconazole— Oteseconazole inhibits BCRP, increasing exposure of rosuvastatin. Monitor for adverse reactions and consider dose reduct…
Rosuvastatin + Rosuvastatin Calcium— 7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of rosuvastatin tablets with …
Rosuvastatin + Segesterone Acetate And Ethinyl Estradiol— Co-administration increases systemic exposure of ethinyl estradiol by approximately 20-25%.
Rosuvastatin + Tafamidis Meglumine— Tafamidis inhibits BCRP, increasing rosuvastatin exposure and toxicity risk. Monitor for toxicities and adjust dosage if…
Rosuvastatin + Tedizolid Phosphate— If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP subs…
Rosuvastatin + Ticagrelor— (7.4) Rosuvastatin plasma concentrations may increase. 7.4 Simvastatin, Lovastatin, Rosuvastatin Ticagrelor increases se…
Rosuvastatin + Warfarin— Rosuvastatin may increase warfarin effects. Monitor INR frequently upon initiation, dose titration, or discontinuation o…

Rosuvastatin + Asciminib⛔Contraindicated

Avoid concomitant use of SCEMBLIX at all recommended doses due to increased risk of rosuvastatin adverse reactions.

Rosuvastatin + Cobicistat⛔Contraindicated

Other HMG-CoA reductase inhibitors: e.g., atorvastatin rosuvastatin ↑ HMG-CoA reductase inhibitors Coadministration of atazanavir and TYBOST with atorvastatin is not recommended. Dosage recommendations with atorvastatin or rosuvastatin are as follows. TYBOST coadministered with atazanavir in adult patients: Rosuvastatin dosage should not exceed 10 mg TYBOST coadministered with darunavir in adult patients: Atorvastatin dosage should not exceed 20 mg Rosuvastatin dosage should not exceed 20 mg Other lipid-modifying agents: lomitapide ↑ lomitapide Coadministration with lomitapide is contraindicated due to potential for markedly increased transaminases.

Rosuvastatin + Darunavir⛔Contraindicated

Lipid Modifying Agents: HMG-CoA reductase inhibitors: lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin Other lipid modifying agents: lomitapide ↑ lovastatin ↑ simvastatin ↑ HMG-CoA reductase inhibitors ↑ lomitapide Co-administration is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. Titrate atorvastatin, pravastatin or rosuvastatin dose carefully and use the lowest necessary dose while monitoring for adverse events.

Rosuvastatin + Darunavir 600 Mg⛔Contraindicated

Lipid Modifying Agents: HMG-CoA reductase inhibitors : lovastatin, simvastatin atorvastatin, pravastatin, rosuvastatin Other lipid modifying agents: lomitapide ↑ lovastatin ↑ simvastatin ↑ HMG-CoA reductase inhibitors ↑ lomitapide Co-administration is contraindicated due to potential for serious reactions such as myopathy including rhabdomyolysis. Titrate atorvastatin, pravastatin or rosuvastatin dose carefully and use the lowest necessary dose while monitoring for adverse events.

Rosuvastatin + Darunavir Ethanolate And Cobicistat⛔Contraindicated

atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvastatin pitavastatin: effect unknown For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety (e.g. Dosage recommendations with atorvastatin or rosuvastatin are as follows: atorvastatin dosage should not exceed 20 mg/day rosuvastatin dosage should not exceed 20 mg/day Other lipid modifying agents: lomitapide ↑ lomitapide Co-administration is contraindicated due to potential for markedly increased transaminases associated with increased plasma concentrations of lomitapide.

Rosuvastatin + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide⛔Contraindicated

e.g., atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin ↑ atorvastatin ↑ fluvastatin ↑ pravastatin ↑ rosuvastatin pitavastatin: effect unknown For atorvastatin, fluvastatin, pitavastatin, pravastatin, and rosuvastatin, start with the lowest recommended dose and titrate while monitoring for safety. Dosage recommendations with atorvastatin or rosuvastatin are as follows: atorvastatin dosage should not exceed 20 mg/day rosuvastatin dosage should not exceed 20 mg/day Other lipid modifying agents : lomitapide ↑ lomitapide Co-administration is contraindicated due to potential for markedly increased transaminases associated with increased plasma concentrations of lomitapide.

Rosuvastatin + Ledipasvir And Sofosbuvir⛔Contraindicated

Combination may significantly increase rosuvastatin exposure. Concomitant use with rosuvastatin is not recommended.

Rosuvastatin + Lopinavir And Ritonavir⛔Contraindicated

Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications (4)]. Titrate rosuvastatin dose carefully and use the lowest necessary dose; do not exceed rosuvastatin 10 mg/day.

Rosuvastatin + Ritonavir⛔Contraindicated

Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications ( 4 ) ] . Titrate atorvastatin and rosuvastatin dose carefully and use the lowest necessary dose.If NORVIR is used with another protease inhibitor, see the complete prescribing information for the concomitant protease inhibitor for details on co-administration with atorvastatin and rosuvastatin.

Rosuvastatin + Ritonavir 100 Mg⛔Contraindicated

Lipid-modifying agents HMG-CoA Reductase Inhibitor: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ↑ lovastatin ↑ simvastatin ↑ atorvastatin ↑ rosuvastatin ↑ lomitapide Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications ( 4 )] . Titrate atorvastatin and rosuvastatin dose carefully and use the lowest necessary dose. If ritonavir is used with another protease inhibitor, see the complete prescribing information for the concomitant protease inhibitor for details on co-administration with atorvastatin and rosuvastatin.

Rosuvastatin + Sofosbuvir, Velpatasvir, And Voxilaprevir⛔Contraindicated

Combination increases rosuvastatin exposure. Use with rosuvastatin tablets is not recommended.

Rosuvastatin + Atazanavir⚠️Major

Intervention: • Sofosbuvir/velpatasvir/voxilaprevir • Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin • Simeprevir • Dasabuvir/ombitasvir/paritaprevir/ritonavir • Elbasvir/grazoprevir • Sofosbuvir/velpatasvir • Glecaprevir/pibrentasvir • Atazanavir/ritonavir • Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.

Rosuvastatin + Capmatinib⚠️Major

Capmatinib increased rosuvastatin exposure more than 2.1-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 10 mg once daily.

Rosuvastatin + Colchicine⚠️Major

Cases of myopathy, including rhabdomyolysis, have been reported with rosuvastatin coadministered with colchicine. Caution is warranted.

Rosuvastatin + Cyclosporine⚠️Major

Cyclosporine increased rosuvastatin exposure 7-fold, significantly increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 5 mg once daily.

Rosuvastatin + Danicopan⚠️Major

Danicopan significantly increased rosuvastatin exposure. Dose should not exceed 10 mg once daily when used concomitantly.

Rosuvastatin + Darolutamide⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily.

Rosuvastatin + Dasabuvir⚠️Major

Rosuvastatin + Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.

Rosuvastatin + Elbasvir⚠️Major

Rosuvastatin + Elbasvir And Grazoprevir⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.

Rosuvastatin + Eltrombopag⚠️Major

OATP1B1 and BCRP substrate; eltrombopag increases exposure. 50% dose reduction was recommended in clinical trials.

Rosuvastatin + Enasidenib⚠️Major

Enasidenib increased rosuvastatin exposure more than 2.4-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 10 mg once daily.

Rosuvastatin + Febuxostat⚠️Major

Febuxostat increased rosuvastatin exposure more than 1.9-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 20 mg once daily.

Rosuvastatin + Fostamatinib⚠️Major

Fostamatinib increased rosuvastatin exposure more than 2.0-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 20 mg once daily.

Rosuvastatin + Gemfibrozil⚠️Major

Avoid concomitant use of gemfibrozil with rosuvastatin. If concomitant use cannot be avoided, initiate rosuvastatin at 5 mg once daily. The dose of rosuvastatin should not exceed 10 mg once daily.

Rosuvastatin + Glecaprevir⚠️Major

Rosuvastatin + Glecaprevir And Pibrentasvir⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.

Rosuvastatin + Grazoprevir⚠️Major

Rosuvastatin + Ledipasvir⚠️Major

Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.

Rosuvastatin + Lopinavir⚠️Major

Rosuvastatin + Ombitasvir⚠️Major

Rosuvastatin + Oral Anticoagulants⚠️Major

Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin and monitor frequently upon initiation or alteration of therapy.

Rosuvastatin + Paritaprevir⚠️Major

Rosuvastatin + Pibrentasvir⚠️Major

Rosuvastatin + Regorafenib⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.

Rosuvastatin + Resmetirom⚠️Major

REZDIFFRA increases plasma concentrations of rosuvastatin; limit daily dosage to 20 mg to reduce risk of statin-related adverse reactions.

Rosuvastatin + Simeprevir⚠️Major

Rosuvastatin + Sofosbuvir⚠️Major

Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.

Rosuvastatin + Teriflunomide⚠️Major

Teriflunomide increased rosuvastatin exposure more than 2.5-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 10 mg once daily.

Rosuvastatin + Tipranavir⚠️Major

HMG-CoA Reductase Inhibitors: Atorvastatin Rosuvastatin ↑ Atorvastatin ↓ Hydroxy-atorvastatin metabolites ↑ Rosuvastatin Avoid co-administration with atorvastatin.

Rosuvastatin + Velpatasvir⚠️Major

Rosuvastatin + Velpatasvir And Sofosbuvir⚠️Major

Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.

Rosuvastatin + Voclosporin⚠️Major

OATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as recommended.

Rosuvastatin + Voxilaprevir⚠️Major

Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin.

Rosuvastatin + Aluminum & Magnesium Hydroxides🟡Moderate

Antacids may reduce rosuvastatin absorption. Administer rosuvastatin at least 2 hours before the antacid.

Rosuvastatin + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol🟡Moderate

Co-administration increases AUC of ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Elagolix🟡Moderate

Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.

Rosuvastatin + Elagolix And Estradiol And Norethisterone🟡Moderate

Statins: rosuvastatin ↓ rosuvastatin Monitor lipid levels and adjust the dose of rosuvastatin, if necessary.

Rosuvastatin + Eltrombopag Olamine🟡Moderate

7.2 Transporters Use caution when concomitantly administering PROMACTA and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). In clinical trials with PROMACTA, a dose reduction of rosuvastatin by 50% was recommended.

Rosuvastatin + Eluxadoline🟡Moderate

Increased exposure to rosuvastatin when co-administered with VIBERZI with a potential for increased risk of myopathy/rhabdomyolysis [ see Clinical Pharmacology ( 12.3 ) ] Intervention: Use the lowest effective dose of rosuvastatin (see prescribing information of rosuvastatin for additional information on recommended dosing).

Rosuvastatin + Fenofibrate🟡Moderate

No clinically significant increase in AUC observed, but risk of myopathy is increased with concomitant use of fenofibrates. Caution should be used.

Rosuvastatin + Fibrates🟡Moderate

Use with fibrates increases risk of adverse skeletal muscle effects. Caution should be used when prescribing with rosuvastatin.

Rosuvastatin + Fosamprenavir🟡Moderate

Fosamprenavir/ritonavir produces little or no change in rosuvastatin exposure. Caution should be exercised when coadministered.

Rosuvastatin + Fostemsavir Tromethamine🟡Moderate

Statins: Rosuvastatin b Atorvastatin Fluvastatin Pitavastatin Simvastatin ↑Rosuvastatin ↑Atorvastatin ↑Fluvastatin ↑Pitavastatin ↑Simvastatin Use the lowest possible starting dose for statins and monitor for statin-associated adverse events.

Rosuvastatin + Leflunomide🟡Moderate

Teriflunomide may increase exposure of rosuvastatin. Dose should not exceed 10 mg once daily.

Rosuvastatin + Lenacapavir Sodium🟡Moderate

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with: darunavir/cobicistat, cobicistat, famotidine, pitavastatin, rosuvastatin, tenofovir alafenamide, and voriconazole.

Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol Tablets🟡Moderate

Rosuvastatin increases AUC of ethinyl estradiol by approximately 20 to 25% when co-administered with certain COCs.

Rosuvastatin + Levonorgestrel And Ethinyl Estradiol And Ferrous Fumarate🟡Moderate

Increases AUC values for ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Levonorgestrel/Ethinyl Estradiol And Ethinyl Estradiol🟡Moderate

Increases systemic exposure of ethinyl estradiol by approximately 20-25 percent.

Rosuvastatin + Momelotinib🟡Moderate

Momelotinib is a BCRP inhibitor that may increase rosuvastatin exposure. Initiate rosuvastatin at 5 mg and do not increase beyond 10 mg once daily.

Rosuvastatin + Niacin🟡Moderate

Lipid-modifying doses (≥1 g/day) of niacin increase risk of adverse skeletal muscle effects with rosuvastatin. Caution should be used.

Rosuvastatin + Norelgestromin And Ethinyl Estradiol🟡Moderate

Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate🟡Moderate

Co-administration increases AUC values for ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Norethindrone Acetate/Ethinyl Estradiol🟡Moderate

Increases AUC values for ethinyl estradiol by approximately 20 to 25%.

Rosuvastatin + Norethindrone And Ethinyl Estradiol🟡Moderate

May increase ethinyl estradiol AUC by approximately 20-25% when co-administered.

Rosuvastatin + Norgestimate And Ethinyl Estradiol🟡Moderate

Co-administration increases AUC of ethinyl estradiol by approximately 20-25%, potentially increasing hormone exposure.

Rosuvastatin + Norgestrel And Ethinyl Estradiol🟡Moderate

Increases AUC of ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Oteseconazole🟡Moderate

Oteseconazole inhibits BCRP, increasing exposure of rosuvastatin. Monitor for adverse reactions and consider dose reduction.

Rosuvastatin + Rosuvastatin Calcium🟡Moderate

7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of rosuvastatin tablets with other drugs that increase the risk of myopathy and rhabdomyolysis. ( 7.1 ) Aluminum and Magnesium Hydroxide Combination Antacids: Administer rosuvastatin tablets at least 2 hours before the antacid. ( 7.2 ) Warfarin: Obtain INR prior to starting rosuvastatin tablets Monitor INR frequently until stable upon initiation, dose titration or discontinuation.

Rosuvastatin + Segesterone Acetate And Ethinyl Estradiol🟡Moderate

Co-administration increases systemic exposure of ethinyl estradiol by approximately 20-25%.

Rosuvastatin + Tafamidis Meglumine🟡Moderate

Tafamidis inhibits BCRP, increasing rosuvastatin exposure and toxicity risk. Monitor for toxicities and adjust dosage if needed.

Rosuvastatin + Tedizolid Phosphate🟡Moderate

If coadministration cannot be avoided, monitor for adverse reactions related to the concomitantly administered BCRP substrates, including rosuvastatin [see Clinical Pharmacology (12.3) ].

Rosuvastatin + Ticagrelor🟡Moderate

(7.4) Rosuvastatin plasma concentrations may increase. 7.4 Simvastatin, Lovastatin, Rosuvastatin Ticagrelor increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Ticagrelor increases serum concentration of rosuvastatin because rosuvastatin is a BCRP substrate [see Clinical Pharmacology (12.3) ] 7.5 Digoxin Ticagrelor inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in ticagrelor therapy [see Clinical Pharmacology (12.3) ].

Rosuvastatin + Warfarin🟡Moderate

Rosuvastatin may increase warfarin effects. Monitor INR frequently upon initiation, dose titration, or discontinuation of rosuvastatin.

Rosuvastatin + Atazanavir And Cobicistatℹ️Unknown

Other HMG-CoA reductase inhibitors: atorvastatin, fluvastatin, pravastatin, rosuvastatin ↑ HMG-CoA reductase inhibitors Coadministration of EVOTAZ with atorvastatin is not recommended. Dosage recommendations with rosuvastatin are as follows. Rosuvastatin dose should not exceed 10 mg/day.

Rosuvastatin + Atazanavir Sulfateℹ️Unknown

atorvastatin, rosuvastatin ↑ atorvastatin ↑ rosuvastatin Titrate atorvastatin dose carefully and use the lowest necessary dose. Rosuvastatin dose should not exceed 10 mg/day.

Rosuvastatin + Brexpiprazoleℹ️Unknown

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI.

Rosuvastatin + Etravirineℹ️Unknown

pravastatin rosuvastatin ↔ etravirine ↔ pravastatin ↔ rosuvastatin No interaction between pravastatin, rosuvastatin and etravirine tablets are expected. pravastatin rosuvastatin ↔ etravirine ↔ pravastatin ↔ rosuvastatin No interaction between pravastatin, rosuvastatin and etravirine tablets are expected.

Rosuvastatin + Fosamprenavir Calciumℹ️Unknown

700 mg twice daily plus ritonavir 100 mg twice daily for 2 weeks 15 ↓14 (↓28 to ↑4) ↔ ↑28 (↑12 to ↑46) (25-O-desacetylrifabutin metabolite) ↑579 (↑479 to ↑698) ↑1,120 (↑965 to ↑1,300) ↑2,510 (↑1,910 to ↑3,300) Rifabutin + 25-O-desacetylrifabutin metabolite NA ↑64 (↑46 to ↑84) NA Rosuvastatin 10-mg single dose 700 mg twice daily plus ritonavir 100 mg twice daily for 7 days ↑45 ↑8 NA Table 13.

Rosuvastatin + Gorafenibℹ️Unknown

Re gorafenib Clinical Impact: Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. I ntervention: In patients taking regorafenib, do not exceed a dose of EZALLOR SPRINKLE 10 mg once daily .

Rosuvastatin + Leflunomide And Diclofenac Sodium Gelℹ️Unknown

For a patient taking leflunomide tablets, the dose of rosuvastatin should not exceed 10 mg once daily. (7) Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking leflunomide tablets.

Rosuvastatin + Letermovirℹ️Unknown

fluvastatin, lovastatin, pravastatin, rosuvastatin ↑ HMG-CoA reductase inhibitors When PREVYMIS is co-administered with these statins, a statin dosage reduction may be necessary .

Rosuvastatin + Maribavirℹ️Unknown

HMG-CoA Reductase Inhibitors Rosuvastatin ↑ Rosuvastatin The patient should be closely monitored for rosuvastatin-related events, especially the occurrence of myopathy and rhabdomyolysis.

Rosuvastatin + Nelfinavir Mesylateℹ️Unknown

HMG-CoA REDUCTASE INHIBITORS Atorvastatin Rosuvastatin ↑ atorvastatin ↑ rosuvastatin Titrate atorvastatin dose carefully and use the lowest necessary dose; do not exceed atorvastatin 40 mg/day.

Rosuvastatin + Pacritinibℹ️Unknown

Rosuvastatin: The dose of rosuvastatin should not exceed 20 mg once daily when concomitantly used with VONJO [see Clinical Pharmacology ( 12.3 )] .

Rosuvastatin + Pretomanidℹ️Unknown

Therefore, it cannot be excluded that co-administration of pretomanid with sensitive OATP1B3 substrates (e.g., valsartan, statins), BCRP substrates (e.g., rosuvastatin, prazosin, glyburide, sulfasalazine) and P-gp substrates (e.g., digoxin, dabigatran etexilate, verapamil) may increase their exposure.

Rosuvastatin + Rolapitantℹ️Unknown

Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).

Rosuvastatin + Vadadustatℹ️Unknown

Rosuvastatin Maximum daily dose of rosuvastatin not to exceed 5 mg.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.